Pure Biologics S.A. (WSE:PUR)

Poland flag Poland · Delayed Price · Currency is PLN
2.472
-0.128 (-4.92%)
Mar 2, 2026, 5:00 PM CET
-82.71%
Market Cap 31.84M
Revenue (ttm) n/a
Net Income (ttm) -17.93M
Shares Out 12.24M
EPS (ttm) -4.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 108,710
Average Volume 152,923
Open 2.598
Previous Close 2.600
Day's Range 2.450 - 2.598
52-Week Range 2.450 - 14.400
Beta 0.70
RSI 25.67
Earnings Date Apr 30, 2026

About Pure Biologics

Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFβ1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the αVβ8 integrin. The company was founded in 2010 and is based in Wroclaw, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 6
Stock Exchange Warsaw Stock Exchange
Ticker Symbol PUR
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.